New hope for rare skin disorder: first human trial launches
NCT ID NCT06539507
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 22 times
Summary
This early-stage study tests a new drug called BCX17725 in healthy people and those with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. The main goals are to check safety and how the body processes the drug. In later parts, researchers will also measure if the drug improves skin symptoms over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dawes Fretzin Clinical Research Group, LLC
RECRUITINGIndianapolis, Indiana, 46250, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Erasmus Universitair Medisch Centrum (EMC)
RECRUITINGRotterdam, 3015 GD, Netherlands
-
Hôpital Saint-Louis
NOT_YET_RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Maastricht Universitair Medisch Centrum (MUMC+)
NOT_YET_RECRUITINGMaastricht, 6229 HX, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern Dermatology CTU
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nucleus Network
ACTIVE_NOT_RECRUITINGBrisbane, Queensland, 4006, Australia
-
Stanford University School of Medicine
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Therapeutics Clinical Research
RECRUITINGSan Diego, California, 92123, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Heidelberg
NOT_YET_RECRUITINGHeidelberg, 69120, Germany
-
Veracity Clinical Research
RECRUITINGBrisbane, Queensland, 4102, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Westmead Hospital - Department of Dermatology
RECRUITINGSydney, New South Wales, 2145, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Center for Clinical Investigation
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.